Background Keverprazan is a novel potassium-competitive acid blocker for the treatment of
acid-related diseases. Aims To evaluate the safety, pharmacokinetics, pharmacodynamics …

Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …

Potassium-competitive acid blockers (P-CABs), such as tegoprazan, are a new and diverse
class of drugs that can completely block the potassium-binding site of gastric H+/K+ ATPase …

Tegoprazan is a novel, potent, and highly selective potassium-competitive acid blocker that
inhibits gastric acid secretion with rapid onset of action and prolonged control of gastric …

This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of
tegoprazan and to predict the drug–drug interaction (DDI) potential between tegoprazan and …

Tegoprazan is a novel orally active potassium-competitive acid blocker (P-CAB), capable of
binding to the K+ binding site of H+/K+-ATPase in a reversible way to inhibit gastric acid …

As a new class of acid inhibitors, potassium-competitive acid blocker (P-CAB) inhibits the
conformational transition of H+, K+-ATPase with subsequent suppression of H+, K+ …

Methods We conducted a prospective, single-arm, single-center, primitive study to verify the
efficacy of a 10-day tegoprazan-based (50-mg dose) concomitant therapy, including …

서론: 칼륨 경쟁적 위산 분비 차단제인 테고프라잔은 CYP3A4 의 잠재적 기질이다.
테고프라잔의 약물-약물 상호작용 임상시험은 제한적이다. 지금까지 수행된 테고프라잔의 약물 …